Agilent Technologies concludes acquisition of ProZyme
02 August 2018 | News
This acquisition expands Agilent’s portfolio of biopharma consumables.
Agilent Technologies has completed the acquisition of ProZyme, Inc., a leading provider of glycan reagents, kits and standards. This acquisition expands Agilent’s portfolio of biopharma consumables.
Founded in 1990, Hayward-Calif. based ProZyme is an industry leading developer and manufacturer of glycan reagents, kits and standards, which are required for efficient sample prep in the analysis of free glycans.
Glycobiology is one of the fastest-growing segments in biopharma, as glycans play diverse roles in biotherapeutics, novel drug development, the study of bacterial physiology, and proteomics research.
The acquisition of ProZyme follows the recent acquisition of Ultra Scientific, a leading provider of chemical standards and certified reference materials.
